Novartis AG EBIT 2010-2024 | NVS
Novartis AG annual and quarterly EBIT history from 2010 to 2024. EBIT can be defined as earnings before interest and taxes.
- Novartis AG EBIT for the quarter ending September 30, 2024 was $3.627B, a 105.85% increase year-over-year.
- Novartis AG EBIT for the twelve months ending September 30, 2024 was $13.596B, a 65.26% increase year-over-year.
- Novartis AG 2023 annual EBIT was $9.769B, a 22.94% increase from 2022.
- Novartis AG 2022 annual EBIT was $7.946B, a 32.02% decline from 2021.
- Novartis AG 2021 annual EBIT was $11.689B, a 15.14% increase from 2020.
Novartis AG Annual EBIT
(Millions of US $) |
| 2023 |
$9,769 |
| 2022 |
$7,946 |
| 2021 |
$11,689 |
| 2020 |
$10,152 |
| 2019 |
$9,086 |
| 2018 |
$8,403 |
| 2017 |
$8,629 |
| 2016 |
$8,268 |
| 2015 |
$8,977 |
| 2014 |
$11,089 |
| 2013 |
$10,983 |
| 2012 |
$11,507 |
| 2011 |
$10,780 |
| 2010 |
$11,526 |
| 2009 |
$9,982 |
Novartis AG Quarterly EBIT
(Millions of US $) |
| 2024-09-30 |
$3,627 |
| 2024-06-30 |
$4,014 |
| 2024-03-31 |
$3,373 |
| 2023-12-31 |
$2,582 |
| 2023-09-30 |
$1,762 |
| 2023-06-30 |
$2,807 |
| 2023-03-31 |
$2,618 |
| 2022-12-31 |
$1,040 |
| 2022-09-30 |
$1,826 |
| 2022-06-30 |
$2,228 |
| 2022-03-31 |
$2,852 |
| 2021-12-31 |
$2,562 |
| 2021-09-30 |
$3,233 |
| 2021-06-30 |
$3,479 |
| 2021-03-31 |
$2,415 |
| 2020-12-31 |
$6,397 |
| 2020-09-30 |
$-1,341 |
| 2020-06-30 |
$2,352 |
| 2020-03-31 |
$2,744 |
| 2019-12-31 |
$1,823 |
| 2019-09-30 |
$2,358 |
| 2019-06-30 |
$2,663 |
| 2019-03-31 |
$2,242 |
| 2018-12-31 |
$1,362 |
| 2018-09-30 |
$2,239 |
| 2018-06-30 |
$2,484 |
| 2018-03-31 |
$2,447 |
| 2017-12-31 |
$2,070 |
| 2017-09-30 |
$2,357 |
| 2017-06-30 |
$2,280 |
| 2017-03-31 |
$1,922 |
| 2016-12-31 |
$1,455 |
| 2016-09-30 |
$2,269 |
| 2016-06-30 |
$2,093 |
| 2016-03-31 |
$2,451 |
| 2015-12-31 |
$1,677 |
| 2015-09-30 |
$2,234 |
| 2015-06-30 |
$2,281 |
| 2015-03-31 |
$2,785 |
| 2014-12-31 |
$2,351 |
| 2014-09-30 |
$2,739 |
| 2014-06-30 |
$3,184 |
| 2014-03-31 |
$2,815 |
| 2013-12-31 |
$2,496 |
| 2013-09-30 |
$2,558 |
| 2013-06-30 |
$3,033 |
| 2013-03-31 |
$2,896 |
| 2012-12-31 |
$2,715 |
| 2012-09-30 |
$2,948 |
| 2012-06-30 |
$3,108 |
| 2012-03-31 |
$2,736 |
| 2011-12-31 |
$1,099 |
| 2011-09-30 |
$2,951 |
| 2011-06-30 |
$3,322 |
| 2011-03-31 |
$3,408 |
| 2010-12-31 |
$2,467 |
| 2010-09-30 |
$2,587 |
| 2010-06-30 |
$2,961 |
| 2010-03-31 |
$3,511 |
| 2009-12-31 |
$2,637 |
| 2009-09-30 |
$2,634 |
| 2009-06-30 |
$2,364 |
| 2009-03-31 |
$2,347 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$211.084B |
$45.440B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
